BrightSpring Health Services, Inc. BTSG

BrightSpring Health Services, Inc. has a fresh governance and ownership file rather than a conventional earnings headline today. The sharpest named development is the 2026-06-12 SEC EDGAR 8-K: on June 11, 2026, the board increased from seven directors to eight and appointed a doctor, with a BrightSpring press release dated June 12 attached to the filing.

The company story on this rail is healthcare services, but the evidence is mostly formal company plumbing: board composition, annual meeting material, selling stockholder activity, an underwriting agreement and filed financials. That matters because the current BTSG file is not built around an announced product launch or clinical approval. It is built around an operating services business whose public record is showing scale, cash and shareholder transactions.

The latest supplied filed financials are from the 10-Q period ending 2026-03-31. BrightSpring reported revenue from contracts with customers, excluding assessed tax, of $3.61B; net income attributable to parent of $148.8M; operating income of $121.4M; diluted EPS of $0.67; assets of $6.21B; liabilities of $4.22B; parent stockholders' equity of $1.98B; cash and cash equivalents of $888.8M; net cash provided by operating activities of $122.9M; payments to acquire property, plant and equipment of $21.5M; inventory, net, of $560.2M; and a decrease in inventories of $254.8M.

No TradingView or chart route is supplied in this evidence pack, so this report does not invent candles, levels, moving averages or price action. The market mechanism that is supplied is an underwritten public offering rail: the 2026-06-05 8-K says BrightSpring entered into an underwriting agreement on June 3, 2026 with KKR Phoenix Aggregator L.P., management selling stockholders and Goldman Sachs & Co., and two 2026-06-05 Form 4 filings say $58.453 was the net price received per share for shares sold pursuant to that underwritten public offering.

The other current source markers are administrative but useful. The evidence list includes a 2026-05-21 8-K for the 2026 Annual Meeting of Stockholders, a 2026-06-05 Schedule 13D/A, a 2026-06-12 Form 3 and Form 4, the SEC EDGAR filing index, the SEC submissions JSON and the SEC companyfacts JSON. Together they make BTSG a filing-led story today: real financial scale, real cash, real inventory and real selling stockholder activity, with limited public colour beyond the filed record.